Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma
Clicks: 1
ID: 317446
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #307 of 332 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 332 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
PURPOSE: Surrogate endpoints are widely used to support interim analyses and regulatory approval of adjuvant therapies in resected solid tumours, yet many lack formal trial-level validation. We evaluated disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogate endpoints for disease-specific survival (DSS) and overall survival (OS) in resected melanoma and assessed the suitability of OS as primary endpoint. PATIENTS AND METHODS: A total of 10,379 patients with AJCC stage I-III melanoma treated between 2000 and 2023 at five international centres were analysed; all underwent sentinel node biopsy. Trial-level surrogacy was assessed using centre-specific log hazard ratios and restricted mean survival time at prespecified surrogate horizons (12 to 48 months), with primary endpoints truncated at 60 months. Individual-level surrogacy was evaluated using Kendall's τ. Prespecified subgroup analyses compared pT-defined IB-IIA and IIB-IIC disease. RESULTS: There were 2,418 DFS events, 1,833 DMFS events, and 1,235 melanoma-specific deaths. Trial-level surrogacy for DFS with DSS was strongest at 24 to 36 months (R2 up to 0.95). DMFS showed consistently high surrogacy for DSS from 24 to 48 months (R2 0.87 to 0.91). Correlations with OS were weak at all horizons (R2 < 0.40). Surrogacy was stage-dependent, with robust performance in pT-defined IIB-IIC disease and limited surrogacy in IB-IIA disease. CONCLUSION: DFS and DMFS are valid surrogate endpoints for DSS in resected melanoma at later time horizons, particularly in higher-risk disease. OS shows attenuated correlation with recurrence-based endpoints, limiting its utility for early endpoint evaluation in adjuvant trials.
| Reference Key |
openalex_W7164858828
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sophie E Orme, Serigne N Lo, Robyn P Saw, Kerwin F Shannon, AndrewJ Spillane, Jonathan R. Stretch, Sydney Ch’ng, Omgo E Nieweg, John F Thompson, Michelle M. Dugan, Danielle K. DePalo, Helana Ghali, Jonathan S Zager, Martin Heaton, Andrew Snelling, Iva Johansson, Roger Olofsson Bagge, Carolyn Nessim, Marc Moncrieff |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag183
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.